Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2022 | Sorafenib | Correction

Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

Authors: Ilaria Romito, Manuela Porru, Maria Rita Braghini, Luca Pompili, Nadia Panera, Annalisa Crudele, Daniela Gnani, Cristiano De Stefanis, Marco Scarsella, Silvia Pomella, Stefano Levi Mortera, Emmanuel de Billy, Adrian Libenzio Conti, Valeria Marzano, Lorenza Putignani, Manlio Vinciguerra, Clara Balsano, Anna Pastore, Rossella Rota, Marco Tartaglia, Carlo Leonetti, Anna Alisi

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2022

Excerpt

Correction to: J Exp Clin Cancer Res 40, 364 (2021). …

Available only for authorised users

Romito I, Porru M, Braghini MR, et al. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. J Exp Clin Cancer Res. 2021;40:364. https://doi.org/10.1186/s13046-021-02154-8.CrossRefPubMedPubMedCentral

Title: Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
Authors: Ilaria Romito
Manuela Porru
Maria Rita Braghini
Luca Pompili
Nadia Panera
Annalisa Crudele
Daniela Gnani
Cristiano De Stefanis
Marco Scarsella
Silvia Pomella
Stefano Levi Mortera
Emmanuel de Billy
Adrian Libenzio Conti
Valeria Marzano
Lorenza Putignani
Manlio Vinciguerra
Clara Balsano
Anna Pastore
Rossella Rota
Marco Tartaglia
Carlo Leonetti
Anna Alisi
Publication date: 01-12-2022
Publisher: BioMed Central
Keyword: Sorafenib
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2022
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-022-02247-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation

Colorectal cancer development is affected by the ECM molecule EMILIN-2 hinging on macrophage polarization via the TLR-4/MyD88 pathway

UBR7 inhibits HCC tumorigenesis by targeting Keap1/Nrf2/Bach1/HK2 and glycolysis

Long noncoding RNA LINC01132 enhances immunosuppression and therapy resistance via NRF1/DPP4 axis in hepatocellular carcinoma

Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies

Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo

Keynote webinar | Spotlight on antibody–drug conjugates in cancer